Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157 patients with advanced cancers who progressed on systemic therapy were tested for 21 mutations in BRAF, EGFR, KRAS, and PIK3CA using the BEAMing...

Full description

Bibliographic Details
Main Authors: Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494976/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494976/

Similar Items